Also trades as: 0I3Q.L (LSE) · $vol 0M
CORT NASDAQ
Corcept Therapeutics Incorporated
1W: -24.8%
1M: -24.2%
3M: -5.8%
YTD: +129.3%
1Y: +20.8%
3Y: +213.7%
5Y: +346.0%
$87.59
+0.47 (+0.53%)
Weekly Expected Move ±11.6%
$66
$76
$86
$96
$106
Credit Risk of going bust: lower than 85% of companies Debt: 0.1% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.01 (down more than 99.9%), Corcept Therapeutics Incorporated would be worth roughly what it owes.
Total debt $9.4M against a stock market value of $9.47B.
Distance to default 11.19 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $5.7M (short-term plus half of long-term), stock volatility 64.9%; Altman Z'' 8.76. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.01 (down more than 99.9%), Corcept Therapeutics Incorporated would be worth roughly what it owes.
Total debt $9.4M against a stock market value of $9.47B.
Distance to default 11.19 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $5.7M (short-term plus half of long-term), stock volatility 64.9%; Altman Z'' 8.76. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.00
Neutral
4 bullish
6 neutral
4 bearish
Articles (7d)
14
Daily Sentiment (7 Days)
Articles (100)
Can Corcept Therapeutics Stock Rally 40% After This Dip?
Can Corcept Therapeutics Stock Rally 40% After This Dip? - Trefis
Corcept Therapeutics Incorporated (CORT) Stock Price, News, Quote & History - Yahoo! Finance Canada
Corcept Therapeutics plunges 20% on Genmab cancer data
Corcept Therapeutics plunges 20% on Genmab cancer data (CORT:NASDAQ) - Seeking Alpha
Genmab rises, Corcept falls on late-stage antibody-conjugate data for ovarian cancer
$CORT stock is down 20% today. Here's what we see in our data. - Quiver Quantitative
Genmab stock surges 9% following positive phase 3 ovarian cancer trial results
Why is Corcept Therapeutics stock tumbling today? - Investing.com
Corcept Therapeutics Incorporat (CORT) Stock Forecasts - Yahoo Finance
2 cash-producing stocks to research further and 1 we find risky
2 cash-producing stocks to research further and 1 we find risky - The Globe and Mail
Corcept Therapeutics Incorporated (CORT) stock price, news, quote and history - Yahoo Finance UK
2 cash-producing stocks to research further and 1 we find risky - StockStory
2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes
Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym?
Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym?
The Zacks Analyst Blog Highlights Ross Stores, Roku, APA, Corcept Therapeutics and Halozyme Therapeutics
The Zacks Analyst Blog Highlights Ross Stores, Roku, APA, Corcept Therapeutics and Halozyme Therapeutics
Corcept Therapeutics (NasdaqCM:CORT) Stock Forecast & Analyst Predictions - Simply Wall Street
Corcept Therapeutics Incorporated $CORT Stock Holdings Cut by First Citizens Bank & Trust Co.
Buy 5 Top-Ranked Non-Tech Nasdaq Stocks to Maximize Q4 Gains
Buy 5 Top-Ranked Non-Tech Nasdaq Stocks to Maximize Q4 Gains
3 Low-Beta Defensive Stocks to Buy as Inflation Continues to Surge
3 Low-Beta Defensive Stocks to Buy as Inflation Continues to Surge
Why Healthcare Stocks Are Hot When the AI Trade Runs Cold
FDA Expands ImmunityBio's Anktiva Label in Bladder Cancer
FDA Expands ImmunityBio's Anktiva Label in Bladder Cancer
Here's Why You Should Add EYPT Stock to Your Portfolio Now
Here's Why You Should Add EYPT Stock to Your Portfolio Now
RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week
RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week
Are Medical Stocks Lagging Aspen Pharmacare (APNHY) This Year?
Are Medical Stocks Lagging Aspen Pharmacare (APNHY) This Year?
1 Cash-Heavy Stock to Keep an Eye On and 2 We Question
Corcept Therapeutics (CORT) Stock Looks Fully Priced For Its Sales Story
Corcept Therapeutics (CORT) Draws Options Attention, Is It Still 18% Below Fair Value?
LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label
LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label
Humana's CenterWell Expansion Gets a Boost From BlackRock's Capital
Humana's CenterWell Expansion Gets a Boost From BlackRock's Capital
Here's Why You Should Add ANRO Stock to Your Portfolio Now
Here's Why You Should Add ANRO Stock to Your Portfolio Now
Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal
Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal
Corcept Therapeutics (CORT) Stock Looks Fully Priced For Its Sales Story - Yahoo Finance
BMY Reports Mixed Phase III Trial Results, Stock Down
BMY Reports Mixed Phase III Trial Results, Stock Down
UNH Tops Q3 Earnings on Lower Medical Costs, Raises '26 Outlook
Are Options Traders Betting on a Big Move in Corcept Therapeutics Stock?
Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why
PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know
These healthcare stocks have the highest EPS revision grade ahead of Q3 results
CORT Stock Slips After-Hours On Weak Q4 Print: Retail Is Watching April FDA Meeting For Relacorilant As Next Catalyst - Stocktwits
3 Reasons to Sell CORT and 1 Stock to Buy Instead - Yahoo Finance
The Zacks Analyst Blog Highlights Abbott, Corcept, Precigen and Bausch Health Companies
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike
Is Aspen Pharmacare (APNHY) Stock Outpacing Its Medical Peers This Year?
Corcept Therapeutics Incorporated $CORT Shares Sold by Engineers Gate Manager LP
328,565 Shares in Corcept Therapeutics Incorporated $CORT Purchased by Bank of America Corp DE
Integrated Wealth Concepts LLC Purchases Shares of 6,423 Corcept Therapeutics Incorporated $CORT
CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer
3 things to look out for on Monday
Catalyst Watch: Trump-Xi in DC, Meta Connect, and McDonald's Investor Day
Merck, Astra, Roche and Corcept among winners of EU drug recommendations this week
10 large and mega-cap U.S. healthcare stocks with the strongest momentum grades
Will Korlym Continue to Aid CORT's Growth Through the Rest of 2026?
Corcept Therapeutics Incorporated $CORT Shares Purchased by California State Teachers Retirement System
Corient Private Wealth LP Takes $569,000 Position in Corcept Therapeutics Incorporated $CORT
The Trade Desk to leave S&P 500 as Bloom Energy, Everpure, Illumina join index
Bloom Energy surges on inclusion to S&P 500; Illumina, Everpure also added
United Therapeutics (UTHR) Down 8% Since Last Earnings Report: Can It Rebound?
Bank of America Corp DE Grows Holdings in Corcept Therapeutics Incorporated $CORT
38,040 Shares in Corcept Therapeutics Incorporated $CORT Acquired by Algert Global LLC
Why Is Corcept (CORT) Down 1.2% Since Last Earnings Report?
Bank of New York Mellon Corp Invests $49.19 Million in Corcept Therapeutics Incorporated $CORT
Corcept (NASDAQ: CORT) director to sell 26,685 shares - Stock Titan
$22M stock sale lined up at Corcept Therapeutics (NASDAQ: CORT) - Stock Titan
BlackRock Inc. Makes New $1.08 Billion Investment in Corcept Therapeutics Incorporated $CORT
Corcept, Revolution Medicines lead ten large-cap healthcare stocks surging in 2026
Corcept Therapeutics (CORT) Stock Analysis: Unveiling an 18% Potential Upside amid Robust Revenue Growth - DirectorsTalk Interviews
Corcept Therapeutics (CORT) Stock Looks Discounted On Sales But Premium Priced On Broader Checks - Simply Wall Street
Handelsbanken Fonder AB Boosts Stock Holdings in Corcept Therapeutics Incorporated $CORT
Corcept Therapeutics (CORT) Stock May Trade At A Discount Yet A Premium On Sales - Yahoo Finance
Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term
AstraZeneca tops pharma growth rankings while Bristol Myers trails amid merger talks
FAS Wealth Partners Inc. Grows Stock Position in Corcept Therapeutics Incorporated $CORT
Avidity Partners Management LP Has $1.21 Million Position in Corcept Therapeutics Incorporated $CORT
CORT Q2 Earnings & Revenues Beat Estimates, 2026 Outlook Raised
Corcept Therapeutics (CORT) Stock Soars 22% After Hours: Here's What You Need To Know - Benzinga
Corcept Therapeutics (CORT) Q2 Earnings and Revenues Surpass Estimates
Here are the major earnings after the close Wednesday
Corcept (NASDAQ:CORT) Reports Bullish Q2 CY2026, Stock Jumps 17.4% - StockStory
Why Corcept (CORT) Stock Is Down Today - Yahoo Finance
Corcept Therapeutics (CORT) Lifted Earnings Outlook, Is The Stock Now Overvalued? - Yahoo Finance
Are Medical Stocks Lagging Corcept Therapeutics (CORT) This Year?
Corcept's CFO Set His Selling Plan the Month the Stock Fell 50% — Here's What Investors Should Know
A Corcept Director Holds 1.5 Million Shares Through a 50% Crash and Rebound
Corcept Insider Sells Shares After an FDA Approval and a $1.05 Billion Outlook
Corcept Resubmits NDA for Relacorilant in Cushing's Syndrome